Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

NCT04902261 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Pancreatic Cancer

Interventions

DRUG: Tislelizumab
DRUG: Nab paclitaxel
DRUG: Gemcitabine

Sponsor

Changhai Hospital